Clinical-stage biotechnology company GeoVax Labs, Inc. (Nasdaq: GOVX) announced it will present its strategic vision and key milestones for 2025 at the upcoming BIO CEO & Investor Conference in New York City. Chairman and CEO David Dodd is scheduled to deliver the presentation on February 10, 2025, offering insights into the company's development of innovative vaccines and immunotherapies targeting cancers and infectious diseases.
The presentation comes at a crucial time for GeoVax, as the company advances several significant clinical programs. Most notably, GeoVax recently secured a BARDA-funded contract to conduct a 10,000-participant Phase 2b clinical trial evaluating their next-generation COVID-19 vaccine, GEO-CM04S1, against an existing approved vaccine. This development represents a major step forward in addressing ongoing challenges in COVID-19 vaccination.
GEO-CM04S1 is currently undergoing three separate Phase 2 clinical trials, each targeting different patient populations. The first trial focuses on immunocompromised patients, particularly those with hematologic cancers, for whom current COVID-19 vaccines may not provide adequate protection. The second trial evaluates its use as a booster vaccine in patients with chronic lymphocytic leukemia (CLL), while the third examines its potential as a more effective and longer-lasting COVID-19 booster for healthy individuals who previously received mRNA vaccines.
Beyond its COVID-19 initiatives, GeoVax is making significant strides in oncology treatment. The company recently completed a multicenter Phase 1/2 clinical trial of Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy for advanced head and neck cancers. A Phase 2 clinical trial combining Gedeptin with an immune checkpoint inhibitor for first recurrent head and neck cancer is scheduled to begin in mid-2025.
These developments are particularly significant for both the medical community and patients, as they represent potential advances in addressing unmet medical needs, especially for immunocompromised individuals and cancer patients. The company's progress in developing dual-purpose technologies that can target both infectious diseases and cancers demonstrates the evolving nature of modern biotechnology and its potential impact on public health.
GeoVax's presentation at the BIO CEO & Investor Conference, taking place February 10-12 at the New York Marriott Marquis, will provide detailed insights into these programs and their potential market impact.
